Methods of treating pulmonary disorders with liposomal amikacin formulations
US10064882B2 · kind B2 · utility
15Cited by
263References
20Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 30, 2017 |
| Grant date | Sep 4, 2018 |
| Priority date | — |
| Expiry date | Jun 30, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/70
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are methods of treating pulmonary disorders comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein: the treatment cycle comprises an administration period of 15 to 75 days, followed by an off period of 15 to 75 days; and the effective dose comprises 100 to 2500 mg of amikacin daily during the administration period.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.